Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma

dc.contributor.authorLarrinaga, Gorka
dc.contributor.authorSolano Iturri, Jon Danel
dc.contributor.authorErrarte, Peio
dc.contributor.authorUnda, Miguel
dc.contributor.authorLoizaga Iriarte, Ana
dc.contributor.authorPérez Fernández, Amparo
dc.contributor.authorEchevarría, Enrique
dc.contributor.authorAsumendi, Aintzane
dc.contributor.authorManini, Claudia
dc.contributor.authorAngulo Cuesta, Javier
dc.contributor.authorEt al.
dc.date.accessioned2024-01-24T10:15:45Z
dc.date.available2024-01-24T10:15:45Z
dc.date.issued2021
dc.description.abstractRenal cell carcinoma (RCC) is a heterogeneous and complex disease with almost no response to chemotherapy. Immune checkpoint inhibitors have achieved great clinical success but no interesting circulating markers of clinical use have developed so far in clear cell renal cell carcinoma (CCRCC). We investigate the diagnostic and prognostic role of plasma PD-1 (sPD-1) and PD-L1 (sPD-L1) proteins for the first time together with the immunohistochemical expression counterpart of these proteins within the tumor front and tumor center in the same sample of patients with renal cancer undergoing surgery. We also investigate these plasma and tissue markers in the population of metastatic patients according to International mRCC Database Consortium (IMDC) prognostic groups and the response to systemic therapy. The independent role of sPD-L1 as a predictor of prognosis and treatment response is demonstrated.spa
dc.description.filiationUEMspa
dc.description.impact6.575 Q1 JCR 2021 ; 1.349 Q1 SJR 2021 ; No data IDR 2021spa
dc.description.sponsorshipBasque Government (ELKARTEK KK2018-00090)spa
dc.description.sponsorshipBasque Government (KK2020/00069)spa
dc.identifier.citationLarrinaga, G., Solano-Iturri, J. D., Errarte, P., Unda, M., Loizaga-Iriarte, A., Pérez-Fernández, A., Echevarría, E., Asumendi, A., Manini, C., Angulo, J. C., & Et. al (2021). Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. Cancers, 13(4), 667. https://doi.org/10.3390/cancers13040667spa
dc.identifier.doi10.3390/cancers13040667
dc.identifier.issn2072-6694
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11268/12598
dc.language.isoengspa
dc.peerreviewedSispa
dc.relation.publisherversionhttps://doi.org/10.3390/cancers13040667spa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessRightsopen accessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.otherPronósticospa
dc.subject.otherCarcinoma de Células Renalesspa
dc.subject.otherBiomarcadores de Tumorspa
dc.subject.unescoCáncerspa
dc.titleSoluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinomaspa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublicationeaadbb3a-67c4-43f5-b477-5fb2318b809a
relation.isAuthorOfPublication.latestForDiscoveryeaadbb3a-67c4-43f5-b477-5fb2318b809a

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Angulo_Cuesta_2021.pdf
Size:
3.86 MB
Format:
Adobe Portable Document Format
Description: